StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
17
This year
1
Publishing Date
2024 - 02 - 26
1
2023 - 04 - 25
1
2023 - 04 - 17
1
2023 - 04 - 11
1
2023 - 03 - 30
1
2023 - 02 - 21
1
2022 - 08 - 12
1
2022 - 06 - 06
1
2022 - 05 - 12
1
2022 - 05 - 04
1
2022 - 04 - 05
1
2022 - 03 - 28
1
2022 - 01 - 06
1
2021 - 12 - 16
1
2021 - 11 - 16
1
2021 - 11 - 11
1
2021 - 11 - 10
1
Sector
Health technology
1
Tags
100
1
Asco
4
Biocanada
1
Biopharma
1
Business
1
Cancer
7
Candidate
1
Car-t
1
Cd33
1
Cel
2
Cell
8
Ceo
1
City
1
Clearance
1
Companies
1
Company
1
Conference
11
Day
1
Designation
1
Drug
1
Earnings
1
Ema
1
Events
3
Fda
2
Fda-approvals
1
Financial
5
Financial results
2
Glioblastoma
12
Global
4
Immunology
2
Immunotherapy
2
Inb-100
9
Inb-200
6
Inb-400
5
Leukemia
7
Market
2
Meeting
15
N/a
47
Offering
4
Ongoing
4
People
2
Pharm-country
17
Phase 1
7
Platform
6
Positive
9
Potential
3
Pre-clinical
2
Preclinical
8
Presentation
2
Program
2
Publication
2
Research
5
Results
10
Stem cell
2
Study
2
T-cell
7
Therapy
10
Treatment
2
Trial
13
Update
7
Entities
Gilead sciences, inc.
1
In8bio inc
17
Symbols
AMRN
14
AMRX
26
ANVS
16
APDN
36
ATNM
19
AVXL
12
BDX
20
BHVN
16
BMY
67
CERT
12
CTSO
12
CTXR
16
DGX
21
ECOR
19
FNCTF
22
HOTH
19
HSIC
14
ICPT
12
IMUX
15
INAB
17
INSM
21
ISEE
14
JNJ
71
KRMD
18
KRYS
12
LEGN
20
LLY
15
LUCD
17
MRK
47
MRNS
23
MS
15
NAOV
14
NRXP
21
ORMP
15
PAVM
17
PDSB
20
PFE
34
PTCT
14
PTPI
16
RCKT
15
REGN
13
RLYB
13
SCYX
12
SDGR
22
SEEL
18
SLS
16
SNGX
20
SNY
55
SNYNF
43
SONN
14
STIM
16
TEVA
19
TEVJF
18
TGTX
14
TNXP
31
TRVI
12
TRVN
16
URGN
25
VRPX
17
YMAB
22
Exchanges
Nasdaq
17
Crawled Date
2024 - 02 - 26
1
2023 - 04 - 25
1
2023 - 04 - 17
1
2023 - 04 - 11
1
2023 - 03 - 30
1
2023 - 02 - 21
1
2022 - 08 - 12
1
2022 - 06 - 06
1
2022 - 05 - 12
1
2022 - 05 - 04
1
2022 - 04 - 06
1
2022 - 03 - 28
1
2022 - 01 - 06
1
2021 - 12 - 16
1
2021 - 11 - 16
1
2021 - 11 - 11
1
2021 - 11 - 10
1
Crawled Time
00:00
1
13:00
2
13:30
1
14:00
4
14:20
1
15:30
1
16:00
1
17:00
1
18:00
1
20:00
1
22:00
2
23:00
1
Source
www.biospace.com
17
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Pharm-country
symbols :
Inab
save search
IN8bio to Present at Upcoming Investor Conferences
Published:
2024-02-26
(Crawled : 16:00)
- biospace.com/
INAB
|
$1.02
-1.92%
110K
|
|
9.13%
|
O:
2.83%
H:
3.06%
C:
0.47%
IN8bio Receives FDA Orphan Drug Designation for INB-400/410 for the Treatment of Newly Diagnosed Glioblastoma
Published:
2023-04-25
(Crawled : 14:20)
- biospace.com/
INAB
|
$1.02
-1.92%
110K
|
|
-65.33%
|
O:
-8.67%
H:
9.49%
C:
-30.29%
inb-400
fda
drug
treatment
designation
glioblastoma
IN8bio Announces Positive Preclinical Data for Gamma-Delta CAR Platform and Launches New CD33 Program at AACR Annual Meeting 2023
Published:
2023-04-17
(Crawled : 14:00)
- biospace.com/
INAB
|
$1.02
-1.92%
110K
|
|
-14.05%
|
O:
5.66%
H:
6.37%
C:
0.9%
cd33
positive
preclinical
meeting
program
platform
IN8bio to Present New Positive Clinical Data from Phase 1 Trial of INB-100 at EBMT 2023 Annual Meeting
Published:
2023-04-11
(Crawled : 14:00)
- biospace.com/
INAB
|
$1.02
-1.92%
110K
|
|
-14.75%
|
O:
10.66%
H:
5.38%
C:
0.0%
inb-100
positive
meeting
trial
IN8bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
Published:
2023-03-30
(Crawled : 22:00)
- biospace.com/
INAB
|
$1.02
-1.92%
110K
|
|
-24.09%
|
O:
2.19%
H:
0.0%
C:
-7.14%
update
financial
results
IN8bio to Present at the H.C. Wainwright Cell Therapy Virtual Conference
Published:
2023-02-21
(Crawled : 17:00)
- biospace.com/
INAB
|
$1.02
-1.92%
110K
|
|
-46.74%
|
O:
9.59%
H:
0.0%
C:
-12.62%
conference
therapy
IN8bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Published:
2022-08-12
(Crawled : 22:00)
- biospace.com/
INAB
|
$1.02
-1.92%
110K
|
|
-47.47%
|
O:
-2.02%
H:
0.52%
C:
-4.64%
update
results
IN8bio Announces Positive Glioblastoma Multiforme (GBM) Clinical Updates from the INB-200 Phase 1 Trial Presented at ASCO 2022
Published:
2022-06-06
(Crawled : 20:00)
- biospace.com/
INAB
|
$1.02
-1.92%
110K
|
|
-60.75%
|
O:
-3.77%
H:
31.76%
C:
5.88%
inb-200
trial
asco
positive
phase 1
glioblastoma
IN8bio Reports First Quarter 2022 Financial Results and Provides Corporate Update
Published:
2022-05-12
(Crawled : 13:00)
- biospace.com/
INAB
|
$1.02
-1.92%
110K
|
|
-53.78%
|
O:
3.89%
H:
3.32%
C:
-1.6%
results
IN8bio to Present at May Investor and Scientific Conferences
Published:
2022-05-04
(Crawled : 13:00)
- biospace.com/
INAB
|
$1.02
-1.92%
110K
|
|
-58.4%
|
O:
10.0%
H:
0.0%
C:
-1.09%
IN8bio to Present at April Investor and Scientific Conferences
Published:
2022-04-05
(Crawled : 00:00)
- biospace.com/
INAB
|
$1.02
-1.92%
110K
|
|
-75.3%
|
O:
-2.38%
H:
9.49%
C:
4.14%
IN8bio Presents Clinical Update from the Ongoing Phase 1 Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant
Published:
2022-03-28
(Crawled : 18:00)
- biospace.com/
INAB
|
$1.02
-1.92%
110K
|
|
-68.86%
|
O:
1.2%
H:
0.0%
C:
-3.85%
inb-100
ongoing
leukemia
trial
therapy
t-cell
phase 1
IN8bio Announces Clinical Updates from the Phase 1 Clinical Trial of its Genetically Modified Gamma-Delta T Cell Therapy in Newly Diagnosed Glioblastoma Multiforme
Published:
2022-01-06
(Crawled : 14:00)
- biospace.com/
INAB
|
$1.02
-1.92%
110K
|
|
-74.51%
|
O:
4.66%
H:
2.34%
C:
2.34%
genetic
trial
cel
phase 1
therapy
t-cell
glioblastoma
IN8bio Provides Update from the Ongoing Phase 1 Clinical Trial of its Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant
Published:
2021-12-16
(Crawled : 13:30)
- biospace.com/
INAB
|
$1.02
-1.92%
110K
|
|
-81.26%
|
O:
3.96%
H:
8.32%
C:
-4.51%
ema
ongoing
leukemia
trial
cel
stem cell
phase 1
therapy
t-cell
IN8bio Appoints Trishna Goswami, M.D. as Chief Medical Officer
Published:
2021-11-16
(Crawled : 15:30)
- biospace.com/
INAB
|
$1.02
-1.92%
110K
|
|
-87.38%
|
O:
1.58%
H:
5.02%
C:
-3.82%
GILD
|
$66.99
-0.06%
3.3M
|
Health Technology
|
-0.59%
|
O:
-0.06%
H:
0.0%
C:
0.0%
IN8bio to Present Preclinical Data on the Potential for Gamma-Delta T-cell Therapy Combinations with PARP and Checkpoint Inhibitors in Solid Tumors
Published:
2021-11-11
(Crawled : 14:00)
- biospace.com/
INAB
|
$1.02
-1.92%
110K
|
|
-87.84%
|
O:
-3.04%
H:
7.24%
C:
-1.81%
solid tumors
potential
therapy
t-cell
preclinical
pre-clinical
IN8bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Published:
2021-11-10
(Crawled : 23:00)
- biospace.com/
INAB
|
$1.02
-1.92%
110K
|
|
-87.72%
|
O:
3.31%
H:
0.48%
C:
-2.29%
financial results
results
Gainers vs Losers
58%
42%
Top 10 Gainers
CZOO
|
$10.52
110.82%
10M
|
CSSE
4
|
$0.3181
108.86%
170M
|
Consumer Services
BOF
|
$1.88
60.68%
98M
|
AMST
|
$3.1
55.0%
66M
|
Technology Services
LICN
|
$0.85
51.79%
13M
|
WIMI
|
$1.03
41.99%
15M
|
Technology Services
SKIL
4
|
$8.045
40.89%
230K
|
Information
MULN
|
News
|
$3.805
39.38%
11M
|
Information
RILY
|
$30.01
38.17%
11M
|
Finance
MTC
|
$3.04
35.71%
6.7M
|
Technology Services
Your saved searches
Save your searches and get alerts when important news are released.